Key facts: RYTM Revenue +80%; Bivamelagon Phase 2 Win; Japan Launch

What happened

Rhythm Pharmaceuticals reported third-quarter 2026 revenue of $92.1 million, up 80% from a year earlier, and a net loss of $42.4 million, or $0.61 per share. It reported positive Phase 2 results for bivamelagon, plans a pivotal Phase 3 trial by the end of 2026, and launched Imcivree in Japan.

Confirmed

Global impact / market context

Higher revenue and a narrower loss could reduce pressure on the company’s cash, while the reported $320.9 million cash balance provides funding for its planned trial. If later trials support bivamelagon, it could add a future product opportunity; Japan sales may also contribute revenue.

Analyst inference

The article combines recent operating results, drug-trial news, and an overseas launch, but gives no sales breakdown for Japan or trial details beyond the planned timing. Needham kept its Buy rating while lowering its price target from $130 to $114, indicating a more cautious valuation view.

Analyst inference

What to watch

1. Watch for the pivotal Phase 3 trial to begin by the end of 2026, as planned, and for updates on when first dosing occurs. Confirmed
2. Look for company updates on whether Imcivree becomes available to more patients in Japan and Europe, and whether access leads to reported sales growth. Analyst inference
3. Check future results for revenue, net loss, and cash changes; continued losses could use funds needed to develop bivamelagon and support commercial launches. Analyst inference

Evidence

• Original source link unavailable